Johnson & Johnson (NYSE: JNJ) is scheduled to report its third-quarter financial results before the markets open on Tuesday. The consensus estimates are calling for $2.03 in earnings per share (EPS) and $20.05 billion in revenue. The same period of last year reportedly had $1.90 in EPS and $19.65 billion in revenue.
The firm’s strong second-quarter results reflected double-digit growth in its Pharmaceutical business and the accelerating sales momentum in its Medical Devices business, driven by the continued growth of its market-leading products and strategic new launches.
Alex Gorsky, board chair and chief executive, commented in the second quarter:
We remain focused on investing in innovation and meeting the needs of our customers by delivering innovative products and solutions that position the company to deliver long-term, sustainable growth. Our talented J&J colleagues are united in our efforts to address some of the most critical health and consumer needs of people around the world.
Also at that time, Johnson & Johnson updated its full-year guidance. The company now expects to see EPS in the range of $8.07 to $8.17 and revenues between $80.5 billion and $81.3 billion. The consensus estimates now are $8.15 in EPS and revenue of $81.23 billion for the year.
Overall, Johnson & Johnson has underperformed the broad markets, with the stock down 2% in the past 52 weeks. In just 2018 alone, the stock is down 4%.
A few analysts weighed in on Johnson & Johnson ahead of the report:
- Credit Suisse has a Buy rating with a $149 price target.
- Wells Fargo has an Outperform rating and a $160 target.
- Jefferies has a Buy rating with a $145 price target.
- Goldman Sachs has a Neutral rating.
Johnson & Johnson shares were last seen trading at $133.95, with a consensus analyst price target of $144.32 and a 52-week trading range of $118.62 to $148.32.